ALDX — Aldeyra Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191
Brief: Aldeyra Therapeutics Resubmits Reproxalap New Drug Application For The Treatment Of Dry Eye Disease
Brief: Aldeyra Therapeutics Inc Says New Drug Application Resubmission Is Anticipated Mid‑2025
Aldeyra Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-US drugmakers, regional banks, chip stocks
U.S. STOCKS ON THE MOVE-Apple, Aldeyra Therapeutics, AllianceBernstein
Aldeyra Therapeutics falls over 70% as FDA declines to approve eye disease drug
US FDA declines to approve Aldeyra's eye disease drug (updated)
Brief: Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease
US FDA declines to approve Aldeyra's eye disease drug
Aldeyra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-InvenTrust Properties, Vistra, MarketAxess
U.S. STOCKS ON THE MOVE-First Foundation, InvenTrust Properties, energy stocks
U.S. STOCKS ON THE MOVE-Southwest Airlines, EQT Corp, Avidity Biosciences
Aldeyra up after resubmitting application for eye disease drug
Brief: Aldeyra Therapeutics Entered Into Fourth Amendment To Loan And Security Agreement
U.S. STOCKS ON THE MOVE-Duolingo, Beyond Meat, Oil stocks